• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Antibody phage display technologies with special reference to angiogenesis.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Smith, Julia
    Kontermann, Roland E
    Embleton, Jim
    Kumar, Shant
    Affiliation
    University of Manchester, Stopford Building, Oxford Rd, Manchester, M13 9PT, UK. Jusmith@fs1.scg.man.ac.uk
    Issue Date
    2005-03
    
    Metadata
    Show full item record
    Abstract
    The presence of blood vessels is a prerequisite for normal development, tissue growth, and tissue repair. However, its abnormal occurrence or absence can also potentiate disease processes. Angiogenic therapies have been used to stimulate blood vessel growth in ischemic conditions such as severe end-stage peripheral vascular disease, ischemic heart disease and stroke and for inhibition of angiogenesis in tumors. The targeting and identification of novel endothelial cell (EC) markers that can ultimately be used in angiogenic strategies is an expanding field but is limited by the availability of reagents. For instance repeated injection of mouse monoclonal antibodies (Mabs) against angiogenic EC, can result in the production of autoantibodies. Therefore, these mouse Mabs cannot be used for therapeutic purposes. Phage display technology was employed in this context to select antibodies, proteins, and peptides against known or novel EC antigens. Furthermore, technologies have been developed that enable the specific targeting of epitopes on cells including the endothelium with high-affinity/avidity antibodies. The focus for these antibody targeting strategies are markers that are unique or up-regulated on angiogenic EC including the vascular endothelial growth factor receptor (VEGFR) KDR, endoglin (CD105), and the extracellular domain B (ED-B) domain of fibronectin (FN). These markers are reviewed herein.
    Citation
    Antibody phage display technologies with special reference to angiogenesis. 2005, 19 (3):331-41 FASEB J.
    Journal
    The FASEB Journal
    URI
    http://hdl.handle.net/10541/76476
    DOI
    10.1096/fj.04-2863rev
    PubMed ID
    15746176
    Type
    Article
    Language
    en
    ISSN
    1530-6860
    ae974a485f413a2113503eed53cd6c53
    10.1096/fj.04-2863rev
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    • Authors: Takahashi N, Haba A, Matsuno F, Seon BK
    • Issue date: 2001 Nov 1
    • Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).
    • Authors: Nettelbeck DM, Miller DW, Jérôme V, Zuzarte M, Watkins SJ, Hawkins RE, Müller R, Kontermann RE
    • Issue date: 2001 Jun
    • Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    • Authors: Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M
    • Issue date: 1997 Jul
    • Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
    • Authors: She X, Matsuno F, Harada N, Tsai H, Seon BK
    • Issue date: 2004 Jan 10
    • Production and characterization of a high-affinity nanobody against human endoglin.
    • Authors: Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Mohammadi M
    • Issue date: 2008 Oct
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.